Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present biOasis Technologies Inc. (OTC: BIOAF).

Full DD Report for BIOAF

You must become a subscriber to view this report.


Recent News from (OTC: BIOAF)

Bioasis Announces Stock Option Grants
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB 3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, inclu...
Source: Business Wire
Date: August, 31 2018 08:46
Aeromics, Inc. Appoints Pharmaceutical and Biotech Veterans Mark Day, Ph.D. and Thomas Zindrick, J.D. to Its Board of Directors
Dr. Day is renowned for his neuroscience and business development accomplishments and Mr. Zindrick is prominently recognized for his legal and corporate governance experience Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-s...
Source: Business Wire
Date: August, 16 2018 08:00
Bioasis Announces Closing of Previously Disclosed Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES BIOASIS TECHNOLOGIES INC . (TSX.V:BTI; OTCQB:BIOAF) (“ Bioasis ” or the “ Company ”), a biopharmaceutical company developing its xB 3 TM...
Source: Business Wire
Date: August, 13 2018 16:26
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending May 31, 2018
BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB 3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, inclu...
Source: Business Wire
Date: July, 30 2018 18:04
Bioasis Welcomes John E. Curran & David M. Wurzer to the Company's Board of Directors
Maha Radhakrishnan, M.D. has resigned as a director due to personal reasons BIOASIS TECHNOLOGIES INC . (TSX.V:BTI; OTCQB:BIOAF) (“ Bioasis ” or the “ Company ”), a biopharmaceutical company developing its xB 3 TM  proprietary platform te...
Source: Business Wire
Date: July, 27 2018 08:30
Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 (TM)-001 Increased Brain Activity
The Company has filed a patent application based on these observations and those data may have broader applicability BIOASIS TECHNOLOGIES INC . (TSX.V:BTI; OTCQB:BIOAF) (“ Bioasis ” or the “ Company ”), a biopharmaceutical company developing it...
Source: Business Wire
Date: July, 25 2018 08:10
Bioasis Announces Non-Brokered Private Placement
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES BIOASIS TECHNOLOGIES INC . (TSX.V:BTI; OTCQB:BIOAF) (“ Bioasis ” or the “ Company ”), a biopharmaceutical company developing its xB 3&#x...
Source: Business Wire
Date: July, 16 2018 08:00
Bioasis and BioAgilytix announce strategic collaboration to advance xb3 TM-001 in brain cancer
Bioasis Technologies ( OTCQB:BIOAF ) and testing services provider BioAgilytix will  partner on the development and validation of bioanalytical methods to support and advance the xB 3 -001 program, Bioasis’ lead candidate to treat HER2+ brain cancer. More news on: Bioasi...
Source: SeekingAlpha
Date: July, 11 2018 09:23
Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis' Lead Investigational Candidate to Treat HER2+ Brain Cancer, to IND Submission and into the Clinic
BIOASIS TECHNOLOGIES INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB 3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, and BIOAGILYTIX , a leading provider o...
Source: Business Wire
Date: July, 11 2018 08:00
Bioasis Technologies reports FY results
Bioasis Technologies ( OTCQB:BIOAF ): FY net loss of $2.26M. More news on: Bioasis Technologies Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Source: SeekingAlpha
Date: June, 27 2018 06:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.353290.34620.353290.34621,000
2018-12-130.330.3570.3570.334,000
2018-12-120.287390.300930.30370.2841,500
2018-12-110.2360.27740.27740.23514,840
2018-12-10N/A0.241565N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-141,0001,000100.0000Short
2018-12-134,0004,000100.0000Short
2018-12-1222,00041,50053.0120Short
2018-12-114,50014,84030.3235Cover
2018-12-0611,00028,00039.2857Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BIOAF.


About biOasis Technologies Inc. (OTC: BIOAF)

Logo for biOasis Technologies Inc. (OTC: BIOAF)

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is focused on creating new drugs that can cross the blood brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases.

 

Contact Information

 

 

Current Management

  • Mark Day / CEO
  • Chris Lowe / CFO
  • Ron Erickson /
  • Michael Hutchison /
  • Mahalakshmi Radhakrishnan /
  • Deborah Rathjen /
  • Nancy Elizabeth Stagliano /

Current Share Structure

  • Market Cap: $25,587,648 - 03/09/2018
  • Issue and Outstanding: 51,661,952 - 10/23/2017
  • Float: 45,955,952 - 10/23/2017

 


Recent Filings from (OTC: BIOAF)

Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: February, 28 2018
Management Discussion and Analysis - Management Discussion and Analysis
Filing Type: Management Discussion and Analysis - Management Discussion and AnalysisFiling Source: OTC Markets
Filing Date: February, 28 2018
Quarterly Report - Quarterly Report
Filing Type: Quarterly Report - Quarterly ReportFiling Source: OTC Markets
Filing Date: January, 22 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: October, 25 2017

 

 


Daily Technical Chart for (OTC: BIOAF)

Daily Technical Chart for (OTC: BIOAF)


Stay tuned for daily updates and more on (OTC: BIOAF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BIOAF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BIOAF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BIOAF and does not buy, sell, or trade any shares of BIOAF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/